Company intelligence / Profile preview

Rabian

Maarssen, Netherlands

Ownership: Private
Development stage: Other

Overview

Rabian is developing cost-effective rabies vaccines utilizing microbial protein production; the main program is funded by a Eurostars grant and is in pre-clinical research. The goal is highly efficacious, affordable, scalable rabies prophylactic products, addressing unmet needs in endemic regions.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Partnerships

Dyadic International

Beyond the preview

Go deeper on Rabian.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabian.

Explore the full profile